AbCellera Announces Closing of Initial Public Offering & Exercise in Full of the Underwriters’ Option to Purchase Additiona...
December 15 2020 - 9:03PM
Business Wire
AbCellera Biologics Inc. (“AbCellera”) (Nasdaq: ABCL), a
technology company that aims to become the centralized operating
system for next-generation antibody discovery, today announced the
closing of its initial public offering of 27,772,500 common shares
at a price to the public of $20.00 per share, which includes the
exercise in full of the underwriters’ option to purchase 3,622,500
additional common shares. All of the common shares were offered by
AbCellera. The gross proceeds from the offering, before deducting
underwriting discounts and commissions and estimated offering
expenses, were approximately $555.5 million. In addition, upon the
closing of the offering, previously issued convertible promissory
notes, with an aggregate principal amount of approximately $90.0
million, converted into 6,093,524 common shares at a price of
$17.00 per share.
Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital
Markets acted as joint book-running managers for the offering.
Registration statements relating to these securities became
effective on December 10, 2020. The offering was made only by means
of a prospectus, copies of which may be obtained from: Credit
Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933
Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800)
221-1037, or by email at usa.prospectus@credit-suisse.com; Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720, or by email at
syndprospectus@stifel.com; Berenberg Capital Markets LLC,
Attention: Investment Banking, 1251 Avenue of the Americas, 53rd
Floor, New York, NY 10020, or by telephone at (646) 949-9000, or by
email at prospectusrequests@berenberg-us.com; SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by
email at syndicate@svbleerink.com; or BMO Capital Markets Corp. at
3 Times Square, 25th Floor, New York, NY 10036, Attention: Equity
Syndicate Department, by telephone at (800) 414-3627, or by email
to bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. AbCellera conducted its initial public offering in
the United States and not in any Canadian jurisdiction.
About AbCellera Biologics
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201215006193/en/
Media: Jessica Yingling, Ph.D. +1 (236) 521-6774
media@abcellera.com Investor Relations: ir@abcellera.com
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Sep 2023 to Sep 2024